论文部分内容阅读
目的探讨同步放疗联合紫杉醇+顺铂(TP)方案治疗中晚期食管癌的疗效及临床分析。方法 2010年6月至2011年6月期间,我院诊治的50例中晚期食管癌患者,随机将其分为对照组(单纯放疗)和观察组(同步放疗联合紫杉醇+顺铂方案治疗),每组各25例,对两组近期疗效、1年局部控制率和远处转移率,以及生存率,进行观察和比较。结果与对照组相比,观察组的总有效率、1年局部控制率、生存率均明显升高,而1年远处转移率显著降低,P<0.05,差异有统计学意义。结论对于中晚期食管癌患者,同步放疗联合紫杉醇+顺铂(TP)方案治疗疗效显著,显著改善患者的预后质量,值得临床推广。
Objective To investigate the efficacy and clinical analysis of concurrent radiotherapy combined with paclitaxel + cisplatin (TP) in the treatment of advanced esophageal cancer. Methods From June 2010 to June 2011, 50 patients with advanced esophageal cancer diagnosed and treated in our hospital were randomly divided into control group (radiotherapy alone) and observation group (concurrent radiotherapy combined with paclitaxel + cisplatin) Each group of 25 cases, the two groups of short-term efficacy, 1 year local control rate and distant metastasis rate, and survival rate were observed and compared. Results Compared with the control group, the total effective rate, local control rate and survival rate in one year increased significantly, while the distant metastasis rate decreased significantly in one year (P <0.05). The difference was statistically significant. Conclusions For patients with advanced esophageal cancer, the combination of concurrent radiotherapy and paclitaxel + cisplatin (TP) has a significant therapeutic effect and significantly improves the prognosis of patients with esophageal cancer. It is worthy of clinical promotion.